Featured Research

from universities, journals, and other organizations

Cellular signals between pancreatic cancer tumors, saliva

Date:
October 9, 2013
Source:
University of California - Los Angeles
Summary:
Pancreatic cancer is one of the deadliest forms of cancer. Most of those with the disease will die within the first year of diagnosis, and just 6 percent will survive five years. The disease is typically diagnosed through an invasive and complicated biopsy. But a discovery by researchers may be one major step toward creating a noninvasive tool that would enable clinicians and oncologists to detect pancreatic cancer through a simple risk assessment test using saliva.

Pancreatic cancer is one of the deadliest forms of cancer. Most of those with the disease will die within the first year of diagnosis, and just 6 percent will survive five years.

The disease is typically diagnosed through an invasive and complicated biopsy. But a discovery by researchers at the UCLA School of Dentistry may be one major step toward creating a noninvasive tool that would enable clinicians and oncologists to detect pancreatic cancer through a simple risk assessment test using saliva.

In a study on a tumor-ridden mouse model, the UCLA researchers were able to definitively validate that pancreatic cancer biomarkers reside in saliva. The team was led by Dr. David Wong, the dentistry school's associate dean of research and the Felix and Mildred Yip Endowed Professor in Dentistry.

The findings are published in a recent issue of the peer-reviewed Journal of Biological Chemistry.

To date, salivary biomarker panels have been successfully developed for cancers of the breast, ovaries, lungs and pancreas. However, researchers in the field of salivary diagnostics are still attempting to understand how biomarkers produced by other parts of the body ultimately appear in the mouth. Scientists have surmised that RNA molecules -- which translate genetic code from DNA to make protein -- are secreted into extracellular spaces and act as an information signal system, representing an innovative model in intercellular signaling.

With this understanding, Wong's research team was able to demonstrate that tumor-derived extracellular RNA molecules are transported through organelles called exosome vesicles that originate at the source of the tumor and are re-processed into saliva as biomarkers. To prove it, the researchers examined mice models with pancreatic cancer whose saliva showed evidence of biomarkers for pancreatic cancer. When they inhibited the production of exosomes at the source of the tumor, the researchers found that the pancreatic cancer biomarkers no longer appeared in the mouse's saliva.

Their discovery supports their claim that tumor-derived exosomes provide a mechanism in the development of disease-specific biomarkers in saliva.

"This paper is significant because it provides credibility to the mechanism of systemic disease detection in saliva," said Wong. "We have been able to substantiate the biological connection between systemic disease and the oral cavity."

The team's findings come on the heels of a $5 million award that Dr. Wong recently received from the National Institutes for Health's Common Fund, a strong statement that saliva is proving to be scientifically credible for the detection of systemic disease and is advancing toward clinical maturation.

"Dr. Wong and his team have provided verifiable evidence to fully explore the use of salivary biomarkers for the detection of life threatening disease in a way that is noninvasive and doesn't cause pain for the patient," said Dr. No-Hee Park, dean of the School of Dentistry. "This new paper truly confirms a mechanistic tie between systemic diseases and their oral manifestations."


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Lau, Y. Kim, D. Chia, N. Spielmann, G. Eibl, D. Elashoff, F. Wei, Y.-L. Lin, A. Moro, T. Grogan, S. Chiang, E. Feinstein, C. Schafer, J. Farrell, D. T. W. Wong. Role of Pancreatic Cancer-derived Exosomes in Salivary Biomarker Development. Journal of Biological Chemistry, 2013; 288 (37): 26888 DOI: 10.1074/jbc.M113.452458

Cite This Page:

University of California - Los Angeles. "Cellular signals between pancreatic cancer tumors, saliva." ScienceDaily. ScienceDaily, 9 October 2013. <www.sciencedaily.com/releases/2013/10/131009100626.htm>.
University of California - Los Angeles. (2013, October 9). Cellular signals between pancreatic cancer tumors, saliva. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/10/131009100626.htm
University of California - Los Angeles. "Cellular signals between pancreatic cancer tumors, saliva." ScienceDaily. www.sciencedaily.com/releases/2013/10/131009100626.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins